Tumor-associated natural killer cells have elevated expression of the checkpoint inhibitory receptor TIGIT. Monoclonal antibody–mediated blockade targeting TIGIT unleashes the anti-tumor activity of both natural killer cells and T cells in preclinical mouse models and efficiently delays tumor growth.
- Ana Stojanovic
- Adelheid Cerwenka